Levofloxacin-d3 (hydrochloride)
CAT:
804-HY-B0330BS1
Size:
Inquire
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Levofloxacin-d3 (hydrochloride)
UNSPSC Description:
Levofloxacin-d3 ((-)-Ofloxacin-d3) hydrochlorideis deuterium labeled Levofloxacin (hydrochloride). Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrochloride shows anti-orthopoxvirus activity[1][2][3][4][5][6].Target Antigen:
Antibiotic; Bacterial; DNA/RNA Synthesis; Isotope-Labeled Compounds; Orthopoxvirus; TopoisomeraseType:
Isotope-Labeled CompoundsRelated Pathways:
Anti-infection;Cell Cycle/DNA Damage;OthersField of Research:
Infection;CancerSmiles:
O=C(C(C1=O)=CN2C(C)COC3=C(N4CCN(C([2H])([2H])[2H])CC4)C(F)=CC1=C23)O.ClMolecular Weight:
400.85References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.|[3]Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.|[4]Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.|[5]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. |[6]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.Shipping Conditions:
Room temperatureClinical Information:
No Development ReportedCAS Number:
1173021-78-7